ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
其他

Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients

Eva Boysen Fynboe Ebert; Tine McCulloch; Karin Holmskov Hansen; Hanne Linnet; Boe Sorensen; Peter MeldgaardAarhus University; AALBORG UNIVERSITY
2020DOI: 10.1016/j.lungcan.2020.03.020
11阅读
引用收藏
分享

摘要

Abstract(#br)Objectives(#br)Tyrosine kinase inhibitors (TKIs) are first line treatment choices for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). However, responses vary among patients, therefore good biomarkers predicting better responses are required. EGFR mutations are detected in the blood from patients as circulating tumour DNA (ctDNA). Studies have shown that clearing ctDNA during first line TKI treatment predicts outcomes for first and second generation TKI treatments. We aimed to investigate the effects on outcome measures of ctDNA clearing in subsequent treatment lines to treatment with the third generation TKI osimertinib.(#br)Methods(#br)In total, 225 patients were included in a prospective, multicentre study, where consecutive blood samples were monitored for EGFR mutations during systemic treatment lines, using the Cobas? EGFR mutation test v2. This study focused on EGFR mutations in ctDNA of 82 systemically pre-treated patients receiving osimertinib.(#br)Results(#br)Clearing all EGFR mutations from the blood after osimertinib treatment, significantly predicted progression-free survival, objective response rates and disease control rates. Primary sensitising EGFR mutations were found in ctDNA in 70 % of patients, and were accompanied by the T790 M mutation in nearly two thirds of cases. The T790 M mutation was cleared in all cases, while the accompanying sensitising mutations did not necessarily clear. However, T790 M clearing without simultaneously clearing of the primary sensitising mutation did not predict clinical responses. Neither the detection of T790 M before osimertinib treatment, nor the presence of EGFR mutations at the time of osimertinib initiation predicted clinical outcomes.(#br)Conclusion(#br)The clearing of EGFR mutations in ctDNA after osimertinib treatment initiation in patients with advanced NSCLC is useful as a positive predictor of clinical outcome.

学科与关键词

关键词
EGFR mutationsCtDNAClearingOutcome predictionOsimertinib

基本信息

发表日期
2020
DOI
10.1016/j.lungcan.2020.03.020

作者

  • E

    Eva Boysen Fynboe Ebert (第一作者)

  • T

    Tine McCulloch

查看全部 6 位作者收起作者
  • K

    Karin Holmskov Hansen

  • H

    Hanne Linnet

  • B

    Boe Sorensen

  • P

    Peter Meldgaard

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417